RT Journal Article
SR Electronic
T1 Short-term effects of irbesartan treatment on microalbuminuria in patients with normotensive type 2 diabetes
JF Saudi Medical Journal
JO Saudi Med J
FD Prince Sultan Military Medical City
SP 1414
OP 1418
VO 29
IS 10
A1 Sevki S. Cetinkalp
A1 Muammer M. Karadeniz
A1 Mehmet A. Erdogan
A1 Gokhan A. Ozgen
A1 Candeger O. Yilmaz
YR 2008
UL http://smj.org.sa/content/29/10/1414.abstract
AB OBJECTIVE: To observe the short-term effects of irbesartan treatment on microalbuminuria in patients with normotensive type 2 diabetes.METHODS: A total of 40 normotensive type 2 diabetes patients (mean age 55.1±11.4 years) who had microalbuminuria were included in this non-comparative and prospective research study. The study took place in Ege University Hospital, Bornova-Izmir, Turkey, between January 2005 and April 2005. Patients were treated with irbesartan 300mg/day for 3 months. Physical examination, medical history, systolic and diastolic blood pressure levels, microalbuminuria, diabetes markers fasting and non-fasting blood glucose, glycosylated hemoglobin [HbA1c], lipid profile, creatinine and urea were obtained at baseline and after 3 months of irbesartan treatment. The primary assessment criterion was the change in microalbuminuria.RESULTS: The mean microalbuminuria level at baseline was 110.8±93.1mg/24 hours. It significantly decreased to 45.6±62.5mg/24 hours at the end of 3 months of irbesartan treatment (p<0.001). When patients were stratified according to the change in the microalbuminuria status after treatment, 90% of them either returned to normo albuminuria or their microalbuminuria decreased. Both diastolic and systolic blood pressures, fasting and non-fasting blood glucose, and HbA1c were found to be significantly decreased after 3 months of irbesartan treatment compared to pre-treatment values. The positive effect of irbesartan on microalbuminuria occurs independently from HbA1c, fasting blood glucose, and blood pressures.CONCLUSION: The short-term treatment of irbesartan is effective to decrease microalbuminuria in normotensive type 2 diabetes patients, independent of its antihypertensive effect. There is a need for multicenter prospective studies to investigate this further.